Long-Term Results with a Slow-Release Gonadotrophin-Releasing Hormone Agonist in Central Precocious Puberty

1991 ◽  
Vol 80 (s372) ◽  
pp. 39-45 ◽  
Author(s):  
W. OOSTDUK ◽  
S. L. S. DROP ◽  
R. J. H. ODINK ◽  
R. HÜMMELINK ◽  
C. J. PARTSCH ◽  
...  
1985 ◽  
Vol 74 (6) ◽  
pp. 945-949 ◽  
Author(s):  
R. BRAUNER ◽  
E. THIBAUD ◽  
P. BISCHOF ◽  
PC. SIZONENKO ◽  
R. RAPPAPORT

2003 ◽  
Vol 15 (6) ◽  
pp. 317 ◽  
Author(s):  
A. Junaidi ◽  
P. E. Williamson ◽  
J. M. Cummins ◽  
G. B. Martin ◽  
M. A. Blackberry ◽  
...  

In the present study, we tested the effect of treatment with a slow-release implant containing the gonadotrophin-releasing hormone agonist DeslorelinTM (Peptech Animal Health Australia, North Ryde, NSW, Australia) on pituitary and testicular function in mature male dogs. Four dogs were treated with Deslorelin (6-mg implant) and four were used as controls (blank implant). In control dogs, there were no significant changes over the 12 months of the study in plasma concentrations of luteinising hormone (LH) or testosterone, or in testicular volume, semen output or semen quality. In Deslorelin-treated dogs, plasma concentrations of LH and testosterone were undetectable after 21 and 27 days, testicular volume fell to 35% of pretreatment values after 14 weeks and no ejaculates could be obtained after 6 weeks. Concentrations returned to the detectable range for testosterone after 44 weeks and for LH after 51 weeks and both were within the normal range after 52 weeks. Semen characteristics had recovered completely by 60 weeks after implantation. At this time, the testes and prostate glands were similar histologically to those of control dogs. We conclude that a single slow-release implant containing 6 mg Deslorelin has potential as a long-term, reversible antifertility agent for male dogs.


1996 ◽  
Vol 75 (4) ◽  
pp. 292-297 ◽  
Author(s):  
W Oostdijk ◽  
B Rikken ◽  
S Schreuder ◽  
B Otten ◽  
R Odink ◽  
...  

2015 ◽  
Vol 11 (1) ◽  
pp. 45 ◽  
Author(s):  
Juliane Léger ◽  
◽  
◽  

Central precocious puberty (CPP) results from premature re-activation of the gonadotropic axis. CPP is much more common in girls than in boys and is idiopathic in most cases. In boys, precocious puberty is more likely to be linked to hypothalamic lesions (≈40%). Recent studies have implicated the inactivation ofMKRN3gene in ‘idiopathic’ CPP. Gonadotropin-releasing hormone agonists are the standard treatment for progressive CPP.


1990 ◽  
Vol 149 (5) ◽  
pp. 308-313 ◽  
Author(s):  
W. Oostdijk ◽  
R. Hümmelink ◽  
R. J. H. Odink ◽  
C. J. Partsch ◽  
S. L. S. Drop ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document